X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 31 filers reported holding X4 PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,881,160 | -36.8% | 2,642,915 | +12.5% | 0.00% | -100.0% |
| Q2 2023 | $4,559,407 | +372.7% | 2,350,210 | +112.0% | 0.00% | – |
| Q1 2023 | $964,555 | +165346.8% | 1,108,684 | +88.7% | 0.00% | – |
| Q4 2022 | $583 | -99.9% | 587,516 | +19.0% | 0.00% | – |
| Q3 2022 | $844,000 | +363.7% | 493,657 | +160.4% | 0.00% | – |
| Q2 2022 | $182,000 | -43.1% | 189,548 | +3.4% | 0.00% | – |
| Q1 2022 | $320,000 | -21.4% | 183,277 | +2.9% | 0.00% | – |
| Q4 2021 | $407,000 | -56.7% | 178,060 | 0.0% | 0.00% | – |
| Q3 2021 | $941,000 | -10.6% | 178,060 | +10.0% | 0.00% | – |
| Q2 2021 | $1,052,000 | -52.7% | 161,917 | -37.3% | 0.00% | – |
| Q1 2021 | $2,222,000 | +34.8% | 258,165 | +0.7% | 0.00% | – |
| Q4 2020 | $1,648,000 | +0.2% | 256,454 | +5.5% | 0.00% | – |
| Q3 2020 | $1,645,000 | -22.6% | 242,988 | +6.6% | 0.00% | – |
| Q2 2020 | $2,124,000 | +1.4% | 227,972 | +8.9% | 0.00% | -100.0% |
| Q1 2020 | $2,094,000 | -45.9% | 209,419 | -42.1% | 0.00% | – |
| Q4 2019 | $3,870,000 | +166.0% | 361,842 | +215.9% | 0.00% | – |
| Q3 2019 | $1,455,000 | -15.0% | 114,532 | +0.4% | 0.00% | – |
| Q2 2019 | $1,711,000 | +663.8% | 114,081 | +784.2% | 0.00% | – |
| Q1 2019 | $224,000 | – | 12,902 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |